MarketPulse

muscular dystrophy

2 articles
The Motley FoolThe Motley Fool··Eric Volkman

JPMorgan Lifts Edgewise Therapeutics on Pipeline Optimism, Stock Surges

JPMorgan raises Edgewise Therapeutics price target to $45, citing positive long-term clinical data for EDG-7500 and sevasemten. Stock rises 2.18%.
AMJBJPMJPMpCJPMpDJPMpJ+5clinical databiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Bridgebio Pharma, Inc.

BridgeBio's BBP-418 Shows Promise as First-Ever LGMD2I/R9 Treatment

BridgeBio reports positive Phase 3 results for BBP-418, showing 31-second improvement in walking tests. FDA submission expected H1 2026, potential U.S. launch late 2026/early 2027.
BBIOFDA approvaldrug development